Initial experience with everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with acute myocardial infarction: a propensity-matched comparison to metallic drug eluting stents 18-month follow-up of the BVS STEMI first study
- 1 May 2016
- journal article
- research article
- Published by Europa Digital & Publishing in EuroIntervention
- Vol. 12 (1), 30-37
- https://doi.org/10.4244/eijv12i1a6
Abstract
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)Keywords
This publication has 24 references indexed in Scilit:
- Bioresorbable vascular scaffold treatment induces the formation of neointimal cap that seals the underlying plaque without compromising the luminal dimensions: a concept based on serial optical coherence tomography dataEuroIntervention, 2015
- A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trialThe Lancet, 2014
- Percutaneous coronary interventions during ST-segment elevation myocardial infarction: current status and future perspectivesEuroIntervention, 2014
- Clinical and intravascular imaging outcomes at 1 and 2 years after implantation of absorb everolimus eluting bioresorbable vascular scaffolds in small vessels. Late lumen enlargement: does bioresorption matter with small vessel size? Insight from the ABSORB cohort B trialHeart, 2012
- Circumferential evaluation of the neointima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation: Can the scaffold cap the plaque?Atherosclerosis, 2012
- Evaluation of the Second Generation of a Bioresorbable Everolimus-Eluting Vascular Scaffold for the Treatment of De Novo Coronary Artery Stenosis: 12-Month Clinical and Imaging OutcomesJournal of the American College of Cardiology, 2011
- 6-Month Clinical Outcomes Following Implantation of the Bioresorbable Everolimus-Eluting Vascular Scaffold in Vessels Smaller or Larger Than 2.5 mmJournal of the American College of Cardiology, 2011
- Evaluation of the Second Generation of a Bioresorbable Everolimus Drug-Eluting Vascular Scaffold for Treatment of De Novo Coronary Artery StenosisCirculation, 2010
- A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methodsThe Lancet, 2009
- Coronary Plaque Erosion Without Rupture Into a Lipid CoreCirculation, 1996